Log In
Print
BCIQ
Print
Print this Print this
 

DCC-2701

  Manage Alerts
Collapse Summary General Information
Company Deciphera Pharmaceuticals LLC
DescriptionOral small molecule targeting vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2) and cMET receptor tyrosine kinase
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2) ; c-Met receptor tyrosine kinase
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors and highly invasive metastatic cancers
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today